DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07370922

CompletedPhase 2

Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

80

actual

Study population

Diabetes (other / unspecified)

Key I/E criterion

—

Primary endpoint

•Glycemic variability

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07370922
Org study IDFMASU MS 794/2024

Timeline

Milestones

Study start2024-11-22actual
Primary completion2025-11-22actual
Study completion2026-01-05actual
Study first posted2026-01-27actual
Last update posted2026-01-27actual

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Diabetes (other / unspecified)

Eligibility

Who can enroll

Minimum age10 Years
Maximum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Age 10-18 years old.

2. Children with TDT according to the Thalassemia International Federation (TIF) guidelines (Farmakis et al., 2022).

3. Children with diabetes mellitus according to the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 guidelines (Libman et al., 2022).

Exclusion criteria

1. Other hemoglobinopathies as alpha thalassemia or sickle thalassemia patients.

2. Other disorders that may affect glucose homeostasis rather than β-TM.

3. Autoimmune disease, collagen diseases, hypo- or hyper-thyroidism, infections, tumors, hematological diseases other than β-TM.

4. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2).

5. Intake of any vitamins or food supplements one month before study and participation in a previous investigational drug study within the three months preceding screening.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Change in glycemic variability using continuous glucose monitoring after 6 months.

Time frame:6 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.